| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 111 | 2023 | 1630 | 11.620 |
Why?
|
| Cognition | 72 | 2023 | 1314 | 9.500 |
Why?
|
| Health Literacy | 19 | 2023 | 105 | 9.090 |
Why?
|
| Alzheimer Disease | 79 | 2023 | 2005 | 8.710 |
Why?
|
| Cognitive Dysfunction | 51 | 2023 | 969 | 8.050 |
Why?
|
| Decision Making | 21 | 2023 | 227 | 7.670 |
Why?
|
| Cognition Disorders | 59 | 2019 | 1032 | 6.470 |
Why?
|
| Aged, 80 and over | 185 | 2023 | 4930 | 6.420 |
Why?
|
| Aged | 217 | 2023 | 9620 | 5.820 |
Why?
|
| Brain | 63 | 2023 | 1727 | 5.770 |
Why?
|
| Independent Living | 18 | 2023 | 285 | 5.280 |
Why?
|
| Dementia | 30 | 2021 | 527 | 4.470 |
Why?
|
| Longitudinal Studies | 77 | 2023 | 1462 | 4.440 |
Why?
|
| Neuropsychological Tests | 80 | 2022 | 1270 | 4.260 |
Why?
|
| Female | 215 | 2023 | 16429 | 4.190 |
Why?
|
| Male | 215 | 2023 | 15870 | 4.150 |
Why?
|
| Humans | 268 | 2023 | 29855 | 3.900 |
Why?
|
| Cohort Studies | 81 | 2023 | 1953 | 3.310 |
Why?
|
| Cerebral Amyloid Angiopathy | 7 | 2023 | 118 | 2.440 |
Why?
|
| Delivery of Health Care | 7 | 2023 | 156 | 2.390 |
Why?
|
| Neurodegenerative Diseases | 7 | 2021 | 117 | 2.300 |
Why?
|
| Cognitive Aging | 5 | 2021 | 81 | 2.160 |
Why?
|
| TDP-43 Proteinopathies | 8 | 2021 | 105 | 2.050 |
Why?
|
| Delay Discounting | 4 | 2023 | 26 | 2.050 |
Why?
|
| Activities of Daily Living | 27 | 2014 | 507 | 2.040 |
Why?
|
| DNA-Binding Proteins | 10 | 2019 | 263 | 1.980 |
Why?
|
| Financial Management | 5 | 2020 | 25 | 1.980 |
Why?
|
| Memory, Episodic | 10 | 2022 | 120 | 1.930 |
Why?
|
| Educational Status | 20 | 2023 | 297 | 1.870 |
Why?
|
| White Matter | 6 | 2020 | 150 | 1.830 |
Why?
|
| Hippocampus | 10 | 2022 | 285 | 1.720 |
Why?
|
| Neuropathology | 5 | 2022 | 81 | 1.600 |
Why?
|
| Memory | 23 | 2018 | 323 | 1.560 |
Why?
|
| Choice Behavior | 4 | 2019 | 56 | 1.560 |
Why?
|
| Residence Characteristics | 15 | 2021 | 216 | 1.510 |
Why?
|
| Economics | 4 | 2019 | 18 | 1.450 |
Why?
|
| Magnetic Resonance Imaging | 18 | 2023 | 1247 | 1.450 |
Why?
|
| Dementia, Vascular | 9 | 2018 | 44 | 1.440 |
Why?
|
| Income | 8 | 2023 | 77 | 1.410 |
Why?
|
| Blood Glucose | 2 | 2022 | 112 | 1.390 |
Why?
|
| Disease Progression | 21 | 2021 | 812 | 1.380 |
Why?
|
| Middle Aged | 78 | 2021 | 9962 | 1.380 |
Why?
|
| Mortality | 10 | 2021 | 86 | 1.340 |
Why?
|
| Hospitalization | 5 | 2019 | 319 | 1.320 |
Why?
|
| Autopsy | 18 | 2021 | 338 | 1.310 |
Why?
|
| Age Factors | 38 | 2021 | 854 | 1.290 |
Why?
|
| Literacy | 2 | 2019 | 15 | 1.250 |
Why?
|
| Amyloid beta-Peptides | 8 | 2023 | 302 | 1.240 |
Why?
|
| Lewy Bodies | 12 | 2021 | 198 | 1.240 |
Why?
|
| Motor Activity | 16 | 2015 | 372 | 1.220 |
Why?
|
| Risk Factors | 40 | 2022 | 2467 | 1.210 |
Why?
|
| Financing, Personal | 5 | 2020 | 19 | 1.180 |
Why?
|
| Fraud | 4 | 2022 | 23 | 1.170 |
Why?
|
| Neoplasms | 9 | 2009 | 257 | 1.140 |
Why?
|
| Muscle Strength | 11 | 2012 | 129 | 1.090 |
Why?
|
| Perception | 3 | 2019 | 83 | 1.080 |
Why?
|
| Prospective Studies | 20 | 2022 | 1823 | 1.070 |
Why?
|
| Goals | 3 | 2010 | 43 | 1.030 |
Why?
|
| Quality of Life | 10 | 2015 | 677 | 1.010 |
Why?
|
| Loneliness | 4 | 2020 | 55 | 1.010 |
Why?
|
| Geriatric Assessment | 12 | 2015 | 221 | 1.010 |
Why?
|
| Nerve Degeneration | 3 | 2014 | 55 | 0.980 |
Why?
|
| Disability Evaluation | 9 | 2015 | 327 | 0.960 |
Why?
|
| Neurofibrillary Tangles | 10 | 2019 | 189 | 0.950 |
Why?
|
| Crime Victims | 2 | 2022 | 25 | 0.950 |
Why?
|
| Proportional Hazards Models | 17 | 2019 | 346 | 0.940 |
Why?
|
| Nervous System Diseases | 5 | 2019 | 150 | 0.940 |
Why?
|
| Incidence | 30 | 2019 | 759 | 0.930 |
Why?
|
| Medicare | 3 | 2023 | 123 | 0.920 |
Why?
|
| Chicago | 14 | 2021 | 867 | 0.910 |
Why?
|
| Government | 1 | 2023 | 3 | 0.900 |
Why?
|
| Awareness | 5 | 2019 | 38 | 0.900 |
Why?
|
| Sex Factors | 27 | 2019 | 498 | 0.870 |
Why?
|
| Hypertension | 3 | 2022 | 272 | 0.860 |
Why?
|
| Life Style | 4 | 2021 | 212 | 0.840 |
Why?
|
| Memory, Short-Term | 4 | 2019 | 103 | 0.840 |
Why?
|
| Arteriolosclerosis | 2 | 2023 | 74 | 0.830 |
Why?
|
| Blood Pressure | 4 | 2022 | 251 | 0.830 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 970 | 0.830 |
Why?
|
| Information Literacy | 3 | 2019 | 9 | 0.820 |
Why?
|
| Atherosclerosis | 1 | 2023 | 75 | 0.800 |
Why?
|
| Metacognition | 1 | 2021 | 3 | 0.800 |
Why?
|
| Brain Mapping | 4 | 2018 | 199 | 0.790 |
Why?
|
| Chronic Disease | 4 | 2017 | 508 | 0.780 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2021 | 8 | 0.780 |
Why?
|
| Elder Abuse | 1 | 2022 | 34 | 0.780 |
Why?
|
| Age of Onset | 2 | 2021 | 110 | 0.770 |
Why?
|
| Reward | 2 | 2019 | 34 | 0.760 |
Why?
|
| Follow-Up Studies | 24 | 2019 | 1859 | 0.730 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 79 | 0.730 |
Why?
|
| Limbic Encephalitis | 1 | 2020 | 11 | 0.730 |
Why?
|
| Plaque, Amyloid | 7 | 2019 | 146 | 0.720 |
Why?
|
| Memory Disorders | 9 | 2019 | 177 | 0.700 |
Why?
|
| Learning | 2 | 2018 | 80 | 0.700 |
Why?
|
| Apolipoprotein E4 | 7 | 2019 | 233 | 0.700 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 19 | 0.680 |
Why?
|
| Depression | 9 | 2021 | 472 | 0.670 |
Why?
|
| Stroke | 1 | 2023 | 294 | 0.660 |
Why?
|
| Risk | 11 | 2019 | 217 | 0.660 |
Why?
|
| Prodromal Symptoms | 1 | 2019 | 19 | 0.650 |
Why?
|
| Adult | 48 | 2022 | 8748 | 0.650 |
Why?
|
| Cerebral Infarction | 8 | 2015 | 154 | 0.630 |
Why?
|
| Agnosia | 2 | 2016 | 10 | 0.630 |
Why?
|
| Mobility Limitation | 7 | 2019 | 97 | 0.620 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2018 | 52 | 0.600 |
Why?
|
| Disabled Persons | 6 | 2019 | 129 | 0.570 |
Why?
|
| United States | 15 | 2023 | 2346 | 0.560 |
Why?
|
| Ambulatory Care | 1 | 2017 | 78 | 0.560 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 194 | 0.550 |
Why?
|
| Postmortem Changes | 1 | 2016 | 34 | 0.540 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 201 | 0.530 |
Why?
|
| Intention | 3 | 2010 | 26 | 0.530 |
Why?
|
| Frail Elderly | 3 | 2014 | 51 | 0.530 |
Why?
|
| Prostatic Hyperplasia | 3 | 2004 | 12 | 0.520 |
Why?
|
| Temporal Lobe | 5 | 2020 | 109 | 0.520 |
Why?
|
| Cognitive Reserve | 3 | 2021 | 38 | 0.510 |
Why?
|
| Regression Analysis | 15 | 2015 | 299 | 0.490 |
Why?
|
| Risk-Taking | 2 | 2011 | 32 | 0.480 |
Why?
|
| Time Factors | 18 | 2020 | 1641 | 0.480 |
Why?
|
| Europe | 14 | 2009 | 85 | 0.470 |
Why?
|
| Frontal Lobe | 4 | 2018 | 85 | 0.470 |
Why?
|
| Sclerosis | 6 | 2020 | 68 | 0.460 |
Why?
|
| Mood Disorders | 2 | 2003 | 31 | 0.440 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2021 | 307 | 0.430 |
Why?
|
| Surveys and Questionnaires | 11 | 2018 | 1186 | 0.430 |
Why?
|
| Cause of Death | 5 | 2009 | 64 | 0.430 |
Why?
|
| Genome-Wide Association Study | 5 | 2021 | 304 | 0.420 |
Why?
|
| Social Class | 3 | 2022 | 65 | 0.420 |
Why?
|
| Health Status | 7 | 2019 | 230 | 0.410 |
Why?
|
| Cerebrovascular Disorders | 4 | 2021 | 139 | 0.410 |
Why?
|
| Child, Preschool | 14 | 2013 | 654 | 0.400 |
Why?
|
| Personality | 3 | 2021 | 67 | 0.400 |
Why?
|
| Child | 17 | 2013 | 1379 | 0.390 |
Why?
|
| Comorbidity | 8 | 2018 | 504 | 0.390 |
Why?
|
| Statistics as Topic | 6 | 2017 | 114 | 0.380 |
Why?
|
| Illinois | 5 | 2020 | 241 | 0.380 |
Why?
|
| Risk Assessment | 7 | 2015 | 685 | 0.380 |
Why?
|
| Urologic Diseases | 3 | 2003 | 5 | 0.370 |
Why?
|
| Environmental Health | 1 | 2010 | 8 | 0.370 |
Why?
|
| Mental Health | 4 | 2019 | 105 | 0.360 |
Why?
|
| Adolescent | 18 | 2018 | 2334 | 0.360 |
Why?
|
| Phobic Disorders | 1 | 2010 | 65 | 0.360 |
Why?
|
| Models, Statistical | 5 | 2012 | 133 | 0.350 |
Why?
|
| Brain Infarction | 4 | 2018 | 74 | 0.350 |
Why?
|
| Socioeconomic Factors | 4 | 2019 | 329 | 0.350 |
Why?
|
| Death | 2 | 2020 | 48 | 0.340 |
Why?
|
| Psychomotor Performance | 6 | 2019 | 220 | 0.340 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 447 | 0.340 |
Why?
|
| Data Collection | 1 | 2010 | 108 | 0.340 |
Why?
|
| Infant | 12 | 2009 | 542 | 0.340 |
Why?
|
| Neurologic Examination | 4 | 2020 | 154 | 0.330 |
Why?
|
| Linear Models | 7 | 2018 | 258 | 0.320 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2020 | 84 | 0.320 |
Why?
|
| Multifactorial Inheritance | 3 | 2018 | 24 | 0.320 |
Why?
|
| Brain Diseases | 3 | 2020 | 83 | 0.310 |
Why?
|
| Lewy Body Disease | 5 | 2018 | 100 | 0.310 |
Why?
|
| Frontotemporal Lobar Degeneration | 2 | 2019 | 28 | 0.310 |
Why?
|
| Self Report | 5 | 2022 | 221 | 0.310 |
Why?
|
| Prognosis | 6 | 2017 | 874 | 0.300 |
Why?
|
| Parkinsonian Disorders | 2 | 2014 | 222 | 0.300 |
Why?
|
| Severity of Illness Index | 11 | 2015 | 1126 | 0.300 |
Why?
|
| Isometric Contraction | 1 | 2007 | 15 | 0.300 |
Why?
|
| 5-alpha Reductase Inhibitors | 2 | 2004 | 3 | 0.300 |
Why?
|
| Brain Neoplasms | 3 | 1994 | 134 | 0.300 |
Why?
|
| Executive Function | 2 | 2021 | 124 | 0.290 |
Why?
|
| Urinary Retention | 2 | 2004 | 11 | 0.290 |
Why?
|
| Adaptation, Psychological | 2 | 2022 | 143 | 0.290 |
Why?
|
| Lower Extremity | 1 | 2007 | 38 | 0.290 |
Why?
|
| Infant, Newborn | 10 | 2009 | 618 | 0.280 |
Why?
|
| Caregivers | 3 | 2005 | 144 | 0.280 |
Why?
|
| Trust | 2 | 2019 | 16 | 0.280 |
Why?
|
| Gait | 2 | 2007 | 406 | 0.280 |
Why?
|
| Urination Disorders | 2 | 2003 | 7 | 0.280 |
Why?
|
| Postural Balance | 1 | 2007 | 122 | 0.270 |
Why?
|
| Sex Characteristics | 3 | 2022 | 135 | 0.260 |
Why?
|
| Primary Prevention | 2 | 2019 | 39 | 0.260 |
Why?
|
| Stress, Psychological | 4 | 2014 | 249 | 0.250 |
Why?
|
| Atrophy | 3 | 2021 | 106 | 0.250 |
Why?
|
| Self Efficacy | 1 | 2005 | 57 | 0.250 |
Why?
|
| Cost of Illness | 1 | 2005 | 55 | 0.250 |
Why?
|
| Sex Distribution | 6 | 2012 | 87 | 0.250 |
Why?
|
| Reference Values | 3 | 2020 | 231 | 0.250 |
Why?
|
| Interpersonal Relations | 3 | 2014 | 105 | 0.250 |
Why?
|
| Age Distribution | 6 | 2007 | 95 | 0.240 |
Why?
|
| Demography | 3 | 2018 | 78 | 0.240 |
Why?
|
| Personal Satisfaction | 2 | 2016 | 48 | 0.240 |
Why?
|
| Gray Matter | 2 | 2016 | 56 | 0.240 |
Why?
|
| Finasteride | 1 | 2004 | 2 | 0.240 |
Why?
|
| Cerebral Cortex | 3 | 2019 | 197 | 0.240 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2004 | 9 | 0.240 |
Why?
|
| Neural Pathways | 3 | 2014 | 83 | 0.240 |
Why?
|
| Longevity | 3 | 2013 | 32 | 0.230 |
Why?
|
| Data Interpretation, Statistical | 2 | 2022 | 98 | 0.230 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2003 | 16 | 0.230 |
Why?
|
| Government Agencies | 1 | 2023 | 4 | 0.230 |
Why?
|
| Anxiety | 3 | 2019 | 157 | 0.230 |
Why?
|
| Mouth Neoplasms | 5 | 1997 | 16 | 0.230 |
Why?
|
| Problem Solving | 1 | 2004 | 47 | 0.230 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 147 | 0.230 |
Why?
|
| Apolipoproteins E | 3 | 2013 | 235 | 0.220 |
Why?
|
| Anxiety Disorders | 2 | 2016 | 169 | 0.220 |
Why?
|
| Individuality | 2 | 2021 | 22 | 0.220 |
Why?
|
| Erectile Dysfunction | 1 | 2003 | 48 | 0.220 |
Why?
|
| Anisotropy | 2 | 2020 | 60 | 0.220 |
Why?
|
| Infarction | 1 | 2023 | 25 | 0.210 |
Why?
|
| Motivation | 1 | 2003 | 101 | 0.210 |
Why?
|
| Models, Theoretical | 1 | 2003 | 94 | 0.210 |
Why?
|
| Survival Rate | 3 | 2012 | 376 | 0.210 |
Why?
|
| Mental Recall | 2 | 2020 | 74 | 0.210 |
Why?
|
| Reaction Time | 2 | 2020 | 124 | 0.210 |
Why?
|
| Mental Status and Dementia Tests | 2 | 2019 | 81 | 0.210 |
Why?
|
| Prefrontal Cortex | 2 | 2014 | 153 | 0.210 |
Why?
|
| Motor Skills | 2 | 2013 | 62 | 0.200 |
Why?
|
| Biomarkers | 3 | 2023 | 704 | 0.200 |
Why?
|
| Predictive Value of Tests | 7 | 2008 | 532 | 0.200 |
Why?
|
| Adenocarcinoma | 4 | 2001 | 194 | 0.190 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 46 | 0.190 |
Why?
|
| Memory and Learning Tests | 1 | 2020 | 7 | 0.190 |
Why?
|
| Serial Learning | 1 | 2020 | 8 | 0.190 |
Why?
|
| Mental Disorders | 2 | 2018 | 142 | 0.190 |
Why?
|
| Psychometrics | 3 | 2014 | 264 | 0.180 |
Why?
|
| Healthy Aging | 1 | 2020 | 13 | 0.180 |
Why?
|
| Neurons | 2 | 2013 | 380 | 0.180 |
Why?
|
| Musculoskeletal Diseases | 2 | 2010 | 41 | 0.180 |
Why?
|
| Antihypertensive Agents | 2 | 2020 | 85 | 0.180 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2002 | 144 | 0.170 |
Why?
|
| Space Perception | 1 | 2019 | 28 | 0.170 |
Why?
|
| Self Concept | 1 | 2020 | 46 | 0.170 |
Why?
|
| Frailty | 1 | 2020 | 39 | 0.170 |
Why?
|
| Korea | 3 | 2003 | 10 | 0.170 |
Why?
|
| Depressive Disorder, Major | 2 | 2016 | 108 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 1998 | 51 | 0.170 |
Why?
|
| Neuronal Plasticity | 1 | 2019 | 43 | 0.170 |
Why?
|
| Emergencies | 1 | 2019 | 39 | 0.160 |
Why?
|
| Computer Graphics | 1 | 1998 | 5 | 0.160 |
Why?
|
| Renal Dialysis | 1 | 1999 | 110 | 0.160 |
Why?
|
| Kidney | 2 | 2010 | 176 | 0.160 |
Why?
|
| Smoking | 6 | 2001 | 194 | 0.160 |
Why?
|
| Lung | 2 | 2009 | 158 | 0.150 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2018 | 20 | 0.150 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 23 | 0.150 |
Why?
|
| Mental Status Schedule | 3 | 2007 | 114 | 0.150 |
Why?
|
| Muscle Weakness | 2 | 2008 | 34 | 0.150 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 285 | 0.150 |
Why?
|
| Registries | 5 | 2003 | 191 | 0.150 |
Why?
|
| Alcohol Drinking | 3 | 1998 | 77 | 0.150 |
Why?
|
| Kidney Failure, Chronic | 1 | 1999 | 158 | 0.150 |
Why?
|
| Salivary Gland Neoplasms | 1 | 1997 | 7 | 0.150 |
Why?
|
| Pain | 2 | 2010 | 397 | 0.140 |
Why?
|
| Brain Stem | 2 | 2016 | 25 | 0.140 |
Why?
|
| Social Behavior | 2 | 2011 | 99 | 0.140 |
Why?
|
| Gene Expression | 1 | 2017 | 232 | 0.140 |
Why?
|
| Lung Neoplasms | 5 | 2003 | 636 | 0.140 |
Why?
|
| RNA, Messenger | 1 | 2017 | 325 | 0.140 |
Why?
|
| Deafness | 1 | 1997 | 16 | 0.140 |
Why?
|
| Personality Development | 1 | 2016 | 6 | 0.140 |
Why?
|
| DNA Methylation | 1 | 2017 | 128 | 0.140 |
Why?
|
| Cochlear Implantation | 1 | 1997 | 22 | 0.140 |
Why?
|
| Locus Coeruleus | 2 | 2013 | 23 | 0.140 |
Why?
|
| Neurotic Disorders | 2 | 2018 | 19 | 0.140 |
Why?
|
| Thyroid Neoplasms | 1 | 1996 | 38 | 0.130 |
Why?
|
| Affect | 1 | 2016 | 65 | 0.130 |
Why?
|
| Fetus | 1 | 2016 | 56 | 0.130 |
Why?
|
| Psychological Tests | 2 | 2015 | 52 | 0.130 |
Why?
|
| Intelligence | 1 | 2016 | 25 | 0.130 |
Why?
|
| Logistic Models | 5 | 2016 | 410 | 0.130 |
Why?
|
| Comprehension | 1 | 2016 | 28 | 0.130 |
Why?
|
| Brain Chemistry | 1 | 2016 | 46 | 0.130 |
Why?
|
| Scotland | 6 | 2007 | 7 | 0.130 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2016 | 40 | 0.130 |
Why?
|
| Psychiatric Status Rating Scales | 5 | 2016 | 351 | 0.130 |
Why?
|
| Vascular Diseases | 2 | 2013 | 53 | 0.130 |
Why?
|
| tau Proteins | 4 | 2023 | 213 | 0.130 |
Why?
|
| Organ Size | 1 | 2015 | 107 | 0.130 |
Why?
|
| Breast Neoplasms | 4 | 2000 | 352 | 0.120 |
Why?
|
| Muscle, Skeletal | 2 | 2008 | 355 | 0.120 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 55 | 0.120 |
Why?
|
| Case-Control Studies | 7 | 2001 | 643 | 0.120 |
Why?
|
| Multilingualism | 1 | 2014 | 11 | 0.120 |
Why?
|
| Harm Reduction | 1 | 2014 | 5 | 0.120 |
Why?
|
| Gyrus Cinguli | 1 | 2014 | 22 | 0.120 |
Why?
|
| Music | 1 | 2014 | 19 | 0.120 |
Why?
|
| Poverty | 1 | 2015 | 97 | 0.120 |
Why?
|
| Anticarcinogenic Agents | 2 | 2000 | 16 | 0.120 |
Why?
|
| Language | 2 | 2014 | 78 | 0.120 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1994 | 24 | 0.110 |
Why?
|
| Medicare Part D | 1 | 2013 | 7 | 0.110 |
Why?
|
| Mesencephalon | 1 | 2013 | 47 | 0.110 |
Why?
|
| Cerebellum | 1 | 2013 | 56 | 0.110 |
Why?
|
| France | 3 | 2003 | 36 | 0.110 |
Why?
|
| Retirement | 2 | 2011 | 11 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2016 | 221 | 0.110 |
Why?
|
| Causality | 3 | 2012 | 52 | 0.110 |
Why?
|
| Psychomotor Disorders | 1 | 2013 | 10 | 0.110 |
Why?
|
| Neuroticism | 3 | 2021 | 34 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 337 | 0.110 |
Why?
|
| Retinoids | 1 | 1992 | 5 | 0.110 |
Why?
|
| Leukoplakia, Oral | 1 | 1992 | 4 | 0.110 |
Why?
|
| Epidemiologic Research Design | 1 | 2012 | 16 | 0.110 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2012 | 26 | 0.110 |
Why?
|
| Gallbladder Neoplasms | 1 | 1992 | 5 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2004 | 399 | 0.100 |
Why?
|
| Child Abuse | 1 | 2012 | 36 | 0.100 |
Why?
|
| Terminally Ill | 1 | 2012 | 5 | 0.100 |
Why?
|
| Models, Psychological | 1 | 2012 | 67 | 0.100 |
Why?
|
| Health Surveys | 2 | 2007 | 96 | 0.100 |
Why?
|
| Urban Population | 2 | 2010 | 143 | 0.100 |
Why?
|
| Emotions | 1 | 2012 | 90 | 0.100 |
Why?
|
| Respiratory Muscles | 2 | 2008 | 18 | 0.100 |
Why?
|
| Alleles | 4 | 2015 | 226 | 0.100 |
Why?
|
| England | 2 | 2003 | 14 | 0.100 |
Why?
|
| Social Environment | 1 | 2011 | 81 | 0.090 |
Why?
|
| Movement Disorders | 1 | 2012 | 148 | 0.090 |
Why?
|
| Odorants | 2 | 2009 | 23 | 0.090 |
Why?
|
| Social Participation | 1 | 2011 | 11 | 0.090 |
Why?
|
| Connecticut | 5 | 1997 | 6 | 0.090 |
Why?
|
| Leg | 2 | 2008 | 49 | 0.090 |
Why?
|
| Motor Skills Disorders | 1 | 2010 | 18 | 0.090 |
Why?
|
| Knowledge | 1 | 2010 | 19 | 0.090 |
Why?
|
| Patient Satisfaction | 2 | 2003 | 297 | 0.090 |
Why?
|
| Potassium | 2 | 2010 | 68 | 0.090 |
Why?
|
| Beer | 1 | 1990 | 1 | 0.090 |
Why?
|
| Alcoholic Beverages | 1 | 1990 | 2 | 0.090 |
Why?
|
| Odds Ratio | 5 | 2007 | 286 | 0.090 |
Why?
|
| Housing for the Elderly | 1 | 2010 | 7 | 0.090 |
Why?
|
| Physical Fitness | 2 | 2008 | 59 | 0.090 |
Why?
|
| Neuroimaging | 2 | 2022 | 138 | 0.090 |
Why?
|
| Muscle Strength Dynamometer | 1 | 2009 | 16 | 0.090 |
Why?
|
| Attitude to Health | 2 | 2003 | 98 | 0.080 |
Why?
|
| Social Adjustment | 1 | 2009 | 29 | 0.080 |
Why?
|
| Prevalence | 3 | 2012 | 494 | 0.080 |
Why?
|
| Body Mass Index | 4 | 2012 | 425 | 0.080 |
Why?
|
| Confidence Intervals | 3 | 2012 | 96 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 1990 | 151 | 0.080 |
Why?
|
| Olfaction Disorders | 1 | 2009 | 53 | 0.080 |
Why?
|
| Community Health Services | 1 | 2009 | 31 | 0.080 |
Why?
|
| Depressive Disorder | 3 | 2007 | 192 | 0.080 |
Why?
|
| Epidemiologic Studies | 2 | 2005 | 23 | 0.080 |
Why?
|
| Forecasting | 2 | 2009 | 117 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2009 | 97 | 0.070 |
Why?
|
| Exercise | 4 | 2012 | 474 | 0.070 |
Why?
|
| Hand Strength | 1 | 2007 | 60 | 0.070 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2007 | 36 | 0.070 |
Why?
|
| Epidemiology | 1 | 2007 | 5 | 0.070 |
Why?
|
| Observation | 1 | 2007 | 16 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2001 | 180 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 803 | 0.070 |
Why?
|
| Laryngeal Neoplasms | 1 | 1987 | 29 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2007 | 103 | 0.070 |
Why?
|
| Netherlands | 2 | 2003 | 10 | 0.070 |
Why?
|
| United Kingdom | 2 | 2016 | 51 | 0.070 |
Why?
|
| Myocardial Infarction | 1 | 2007 | 175 | 0.070 |
Why?
|
| Exercise Therapy | 1 | 2007 | 112 | 0.070 |
Why?
|
| Cerebral Arteries | 1 | 2005 | 31 | 0.070 |
Why?
|
| Genetic Loci | 2 | 2018 | 61 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2003 | 77 | 0.070 |
Why?
|
| Interview, Psychological | 1 | 2005 | 36 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2019 | 3325 | 0.060 |
Why?
|
| Home Nursing | 1 | 2005 | 19 | 0.060 |
Why?
|
| Sertraline | 2 | 2002 | 23 | 0.060 |
Why?
|
| Social Support | 2 | 2020 | 186 | 0.060 |
Why?
|
| Models, Biological | 1 | 1987 | 347 | 0.060 |
Why?
|
| Italy | 4 | 1998 | 15 | 0.060 |
Why?
|
| Acute Disease | 2 | 2004 | 225 | 0.060 |
Why?
|
| New South Wales | 2 | 1994 | 4 | 0.060 |
Why?
|
| Libido | 1 | 2003 | 7 | 0.060 |
Why?
|
| Ejaculation | 1 | 2003 | 8 | 0.060 |
Why?
|
| Young Adult | 3 | 2018 | 1969 | 0.060 |
Why?
|
| Heterozygote | 2 | 2015 | 103 | 0.060 |
Why?
|
| Australia | 3 | 1999 | 46 | 0.060 |
Why?
|
| Vital Statistics | 1 | 2003 | 1 | 0.060 |
Why?
|
| Azasteroids | 1 | 2003 | 2 | 0.060 |
Why?
|
| Health Care Surveys | 1 | 2003 | 67 | 0.060 |
Why?
|
| Genotype | 2 | 2015 | 409 | 0.050 |
Why?
|
| Carcinoma, Small Cell | 2 | 2001 | 71 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 411 | 0.050 |
Why?
|
| Observer Variation | 1 | 2003 | 119 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2003 | 310 | 0.050 |
Why?
|
| Program Evaluation | 1 | 2003 | 135 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2021 | 7 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2003 | 219 | 0.050 |
Why?
|
| Epidemiologic Methods | 2 | 2015 | 20 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2021 | 21 | 0.050 |
Why?
|
| Health Behavior | 2 | 2014 | 159 | 0.050 |
Why?
|
| Brazil | 1 | 2021 | 37 | 0.050 |
Why?
|
| Antidepressive Agents | 1 | 2002 | 103 | 0.050 |
Why?
|
| beta-Lactamases | 1 | 2021 | 72 | 0.050 |
Why?
|
| Spouses | 1 | 2000 | 26 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2021 | 178 | 0.050 |
Why?
|
| Switzerland | 2 | 1990 | 9 | 0.040 |
Why?
|
| Machine Learning | 1 | 2020 | 54 | 0.040 |
Why?
|
| Selenium | 1 | 2000 | 7 | 0.040 |
Why?
|
| Nails | 1 | 2000 | 2 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 558 | 0.040 |
Why?
|
| New Zealand | 1 | 1999 | 13 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2000 | 67 | 0.040 |
Why?
|
| Frontotemporal Dementia | 1 | 2019 | 14 | 0.040 |
Why?
|
| Sleep Wake Disorders | 1 | 2000 | 148 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2000 | 110 | 0.040 |
Why?
|
| Women's Health | 1 | 2001 | 247 | 0.040 |
Why?
|
| Wales | 1 | 1998 | 4 | 0.040 |
Why?
|
| Spain | 1 | 1998 | 20 | 0.040 |
Why?
|
| Proteomics | 1 | 2019 | 93 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 1998 | 25 | 0.040 |
Why?
|
| Testicular Neoplasms | 1 | 1998 | 23 | 0.040 |
Why?
|
| Japan | 4 | 2001 | 11 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 411 | 0.040 |
Why?
|
| Algorithms | 1 | 2021 | 401 | 0.040 |
Why?
|
| Religious Personnel | 1 | 2018 | 11 | 0.040 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2017 | 11 | 0.040 |
Why?
|
| alpha-Macroglobulins | 1 | 2017 | 12 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 43 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 38 | 0.040 |
Why?
|
| Gingival Neoplasms | 1 | 1997 | 1 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 1998 | 99 | 0.040 |
Why?
|
| Sampling Studies | 3 | 2002 | 29 | 0.040 |
Why?
|
| Czechoslovakia | 2 | 2001 | 2 | 0.040 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 1996 | 5 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 1996 | 20 | 0.030 |
Why?
|
| Time | 1 | 1996 | 17 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2016 | 41 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2016 | 6 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1996 | 16 | 0.030 |
Why?
|
| Computational Biology | 1 | 2016 | 24 | 0.030 |
Why?
|
| Radiotherapy | 1 | 1996 | 53 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2016 | 19 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 24 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 140 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 39 | 0.030 |
Why?
|
| SEER Program | 1 | 1996 | 38 | 0.030 |
Why?
|
| Diet | 2 | 2000 | 172 | 0.030 |
Why?
|
| Speech Perception | 1 | 1997 | 48 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2016 | 80 | 0.030 |
Why?
|
| Urology | 1 | 1995 | 16 | 0.030 |
Why?
|
| Family Practice | 1 | 1995 | 20 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 80 | 0.030 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 128 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 29 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 96 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 86 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 364 | 0.030 |
Why?
|
| Life Change Events | 1 | 2014 | 36 | 0.030 |
Why?
|
| Canada | 2 | 1994 | 56 | 0.030 |
Why?
|
| Empathy | 1 | 2014 | 36 | 0.030 |
Why?
|
| Carcinoma | 1 | 1994 | 59 | 0.030 |
Why?
|
| Raphe Nuclei | 1 | 2013 | 8 | 0.030 |
Why?
|
| Ventral Tegmental Area | 1 | 2013 | 12 | 0.030 |
Why?
|
| Lip Neoplasms | 1 | 1993 | 2 | 0.030 |
Why?
|
| World Health Organization | 3 | 2003 | 19 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 81 | 0.030 |
Why?
|
| Fathers | 1 | 1994 | 22 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 97 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 44 | 0.030 |
Why?
|
| Endophenotypes | 1 | 2013 | 12 | 0.030 |
Why?
|
| Religion | 1 | 2013 | 40 | 0.030 |
Why?
|
| Isotretinoin | 1 | 1992 | 8 | 0.030 |
Why?
|
| Vitamin A | 1 | 1992 | 6 | 0.030 |
Why?
|
| Carotenoids | 1 | 1992 | 8 | 0.030 |
Why?
|
| Poland | 1 | 1992 | 6 | 0.030 |
Why?
|
| Coffee | 1 | 1992 | 4 | 0.030 |
Why?
|
| Substantia Nigra | 1 | 2013 | 149 | 0.030 |
Why?
|
| Neocortex | 1 | 2012 | 34 | 0.030 |
Why?
|
| Pregnancy | 1 | 1994 | 388 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1992 | 42 | 0.030 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 1992 | 1 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 1992 | 46 | 0.030 |
Why?
|
| Actigraphy | 1 | 2012 | 98 | 0.030 |
Why?
|
| Energy Intake | 1 | 1992 | 66 | 0.030 |
Why?
|
| Games, Experimental | 1 | 2011 | 9 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2012 | 53 | 0.020 |
Why?
|
| Probability | 1 | 2011 | 94 | 0.020 |
Why?
|
| Parents | 1 | 2012 | 106 | 0.020 |
Why?
|
| Nerve Net | 1 | 2011 | 54 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 1992 | 67 | 0.020 |
Why?
|
| Oxygen | 1 | 2011 | 86 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1992 | 51 | 0.020 |
Why?
|
| Bulgaria | 1 | 1990 | 1 | 0.020 |
Why?
|
| Germany, West | 1 | 1990 | 1 | 0.020 |
Why?
|
| Yugoslavia | 1 | 1990 | 1 | 0.020 |
Why?
|
| Denmark | 1 | 1990 | 12 | 0.020 |
Why?
|
| Visual Perception | 1 | 2011 | 50 | 0.020 |
Why?
|
| Research Design | 1 | 2012 | 214 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1992 | 106 | 0.020 |
Why?
|
| Wine | 1 | 1990 | 8 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 142 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 1989 | 19 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2009 | 33 | 0.020 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 1989 | 1 | 0.020 |
Why?
|
| Microcirculation | 1 | 2009 | 39 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2003 | 3561 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2009 | 59 | 0.020 |
Why?
|
| Animals | 1 | 1998 | 4640 | 0.020 |
Why?
|
| Extremities | 1 | 2008 | 33 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2009 | 73 | 0.020 |
Why?
|
| Catholicism | 1 | 2007 | 21 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2007 | 29 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2007 | 55 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2007 | 32 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2007 | 32 | 0.020 |
Why?
|
| Clergy | 1 | 2007 | 90 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2007 | 140 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 332 | 0.020 |
Why?
|
| Porphyrias | 1 | 1985 | 1 | 0.020 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 1985 | 28 | 0.020 |
Why?
|
| Cohort Effect | 2 | 1994 | 2 | 0.020 |
Why?
|
| Dutasteride | 1 | 2003 | 2 | 0.010 |
Why?
|
| Death Certificates | 1 | 2003 | 1 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2003 | 120 | 0.010 |
Why?
|
| Citalopram | 1 | 2002 | 7 | 0.010 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2002 | 28 | 0.010 |
Why?
|
| Outpatients | 1 | 2002 | 54 | 0.010 |
Why?
|
| Slovakia | 1 | 2001 | 1 | 0.010 |
Why?
|
| Bendroflumethiazide | 1 | 1980 | 1 | 0.010 |
Why?
|
| Metolazone | 1 | 1980 | 2 | 0.010 |
Why?
|
| Diuretics | 1 | 1980 | 17 | 0.010 |
Why?
|
| Hawaii | 1 | 2000 | 3 | 0.010 |
Why?
|
| Neutron Activation Analysis | 1 | 2000 | 1 | 0.010 |
Why?
|
| Toes | 1 | 2000 | 5 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2000 | 118 | 0.010 |
Why?
|
| beta Carotene | 1 | 1998 | 7 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2000 | 198 | 0.010 |
Why?
|
| Vitamin E | 1 | 1998 | 27 | 0.010 |
Why?
|
| Postmenopause | 1 | 1998 | 61 | 0.010 |
Why?
|
| Antioxidants | 1 | 1998 | 61 | 0.010 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 1994 | 3 | 0.010 |
Why?
|
| North America | 1 | 1994 | 39 | 0.010 |
Why?
|
| Public Health | 1 | 1994 | 62 | 0.010 |
Why?
|
| Tongue Neoplasms | 1 | 1992 | 16 | 0.010 |
Why?
|
| Pleural Neoplasms | 1 | 1992 | 9 | 0.010 |
Why?
|
| Parasympathetic Nervous System | 1 | 1985 | 2 | 0.000 |
Why?
|
| Valsalva Maneuver | 1 | 1985 | 4 | 0.000 |
Why?
|
| Sympathetic Nervous System | 1 | 1985 | 9 | 0.000 |
Why?
|
| Respiration | 1 | 1985 | 35 | 0.000 |
Why?
|
| Posture | 1 | 1985 | 79 | 0.000 |
Why?
|
| Muscle Contraction | 1 | 1985 | 83 | 0.000 |
Why?
|
| Heart Rate | 1 | 1985 | 152 | 0.000 |
Why?
|